A

Agenus
D

AGEN

5.96000
USD
0.46
(8.36%)
مغلق
حجم التداول
27,646
الربح لكل سهم
2
العائد الربحي
-
P/E
0
حجم السوق
163,404,426
أصول ذات صلة
A
ADVM
0.03500
(1.55%)
2.29500 USD
A
APPS
0.17000
(2.91%)
6.01000 USD
A
ARDX
0.08000
(1.90%)
4.28000 USD
A
ASC
0.052
(0.51%)
10.250 USD
A
ATRA
0.39000
(4.74%)
8.62000 USD
A
AVXL
0.250
(2.37%)
10.790 USD
N
NERV
0.01000
(0.58%)
1.72000 USD
A
AIM
0.21500
(2.50%)
8.82500 USD
المزيد
الأخبار المقالات

العنوان: Agenus

القطاع: Healthcare
الصناعة: Biotechnology
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).